PMC:7242013 / 921-2492 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T11","span":{"begin":190,"end":195},"obj":"Body_part"},{"id":"T12","span":{"begin":676,"end":681},"obj":"Body_part"},{"id":"T13","span":{"begin":935,"end":940},"obj":"Body_part"},{"id":"T14","span":{"begin":1143,"end":1148},"obj":"Body_part"},{"id":"T15","span":{"begin":1201,"end":1206},"obj":"Body_part"},{"id":"T16","span":{"begin":1270,"end":1275},"obj":"Body_part"},{"id":"T17","span":{"begin":1397,"end":1402},"obj":"Body_part"}],"attributes":[{"id":"A11","pred":"fma_id","subj":"T11","obj":"http://purl.org/sig/ont/fma/fma7197"},{"id":"A12","pred":"fma_id","subj":"T12","obj":"http://purl.org/sig/ont/fma/fma7197"},{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma7197"},{"id":"A14","pred":"fma_id","subj":"T14","obj":"http://purl.org/sig/ont/fma/fma7197"},{"id":"A15","pred":"fma_id","subj":"T15","obj":"http://purl.org/sig/ont/fma/fma7197"},{"id":"A16","pred":"fma_id","subj":"T16","obj":"http://purl.org/sig/ont/fma/fma7197"},{"id":"A17","pred":"fma_id","subj":"T17","obj":"http://purl.org/sig/ont/fma/fma7197"}],"text":"To navigate through the stormy unchartered ocean of SARS‐coV‐2 infections and coronavirus disease 2019 (COVID‐19), all practicing hepatologists and other clinicians caring for patients with liver disease need guidance based on the best documented and rapidly evolving knowledge regarding SARS‐CoV‐2 infection and COVID‐19. Prevention of SARS‐CoV‐2 transmission requires the redesign of patient workflow and other measures ensuring delivery of elective and emergency hepatology services without compromising the safety of patients and medical personnel. 1 , 2 Moreover, prevention of severe COVID‐19 and related mortality requires updating management of persons with chronic liver disease (CLD) to diagnose COVID‐19 and being vigilant for drug‐drug interactions and other potential complications of COVID‐19 in persons with CLD. 3 To respond to an urgent need for such information, the Asian Pacific Association for the Study of the Liver (APASL) recently published recommendations of an expert committee to guide infection control and clinical management of patients with CLD during the COVID‐19 pandemic. 4 Previously, two other regional liver associations, American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL), convened expert panels with the same objectives. 5 , 6 This review summarizes the recommendations of the three liver associations for clinical practices to prevent SARS‐CoV‐2 transmission and protect persons with CLD from health risks posed by the emerging COVID‐19 pandemic (Table 1)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"54","span":{"begin":176,"end":184},"obj":"Species"},{"id":"55","span":{"begin":337,"end":347},"obj":"Species"},{"id":"56","span":{"begin":386,"end":393},"obj":"Species"},{"id":"57","span":{"begin":521,"end":529},"obj":"Species"},{"id":"58","span":{"begin":655,"end":662},"obj":"Species"},{"id":"59","span":{"begin":812,"end":819},"obj":"Species"},{"id":"60","span":{"begin":1061,"end":1069},"obj":"Species"},{"id":"61","span":{"begin":1450,"end":1460},"obj":"Species"},{"id":"62","span":{"begin":1486,"end":1493},"obj":"Species"},{"id":"63","span":{"begin":52,"end":73},"obj":"Disease"},{"id":"64","span":{"begin":78,"end":102},"obj":"Disease"},{"id":"65","span":{"begin":104,"end":112},"obj":"Disease"},{"id":"66","span":{"begin":190,"end":203},"obj":"Disease"},{"id":"67","span":{"begin":288,"end":308},"obj":"Disease"},{"id":"68","span":{"begin":313,"end":321},"obj":"Disease"},{"id":"69","span":{"begin":592,"end":600},"obj":"Disease"},{"id":"70","span":{"begin":613,"end":622},"obj":"Disease"},{"id":"71","span":{"begin":668,"end":689},"obj":"Disease"},{"id":"72","span":{"begin":708,"end":716},"obj":"Disease"},{"id":"73","span":{"begin":800,"end":808},"obj":"Disease"},{"id":"74","span":{"begin":1016,"end":1025},"obj":"Disease"},{"id":"75","span":{"begin":1090,"end":1098},"obj":"Disease"},{"id":"76","span":{"begin":1201,"end":1215},"obj":"Disease"},{"id":"77","span":{"begin":1543,"end":1551},"obj":"Disease"}],"attributes":[{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"Tax:9606"},{"id":"A55","pred":"tao:has_database_id","subj":"55","obj":"Tax:2697049"},{"id":"A56","pred":"tao:has_database_id","subj":"56","obj":"Tax:9606"},{"id":"A57","pred":"tao:has_database_id","subj":"57","obj":"Tax:9606"},{"id":"A58","pred":"tao:has_database_id","subj":"58","obj":"Tax:9606"},{"id":"A59","pred":"tao:has_database_id","subj":"59","obj":"Tax:9606"},{"id":"A60","pred":"tao:has_database_id","subj":"60","obj":"Tax:9606"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"Tax:2697049"},{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"Tax:9606"},{"id":"A63","pred":"tao:has_database_id","subj":"63","obj":"MESH:C000657245"},{"id":"A64","pred":"tao:has_database_id","subj":"64","obj":"MESH:C000657245"},{"id":"A65","pred":"tao:has_database_id","subj":"65","obj":"MESH:C000657245"},{"id":"A66","pred":"tao:has_database_id","subj":"66","obj":"MESH:D008107"},{"id":"A67","pred":"tao:has_database_id","subj":"67","obj":"MESH:C000657245"},{"id":"A68","pred":"tao:has_database_id","subj":"68","obj":"MESH:C000657245"},{"id":"A69","pred":"tao:has_database_id","subj":"69","obj":"MESH:C000657245"},{"id":"A70","pred":"tao:has_database_id","subj":"70","obj":"MESH:D003643"},{"id":"A71","pred":"tao:has_database_id","subj":"71","obj":"MESH:D058625"},{"id":"A72","pred":"tao:has_database_id","subj":"72","obj":"MESH:C000657245"},{"id":"A73","pred":"tao:has_database_id","subj":"73","obj":"MESH:C000657245"},{"id":"A74","pred":"tao:has_database_id","subj":"74","obj":"MESH:D007239"},{"id":"A75","pred":"tao:has_database_id","subj":"75","obj":"MESH:C000657245"},{"id":"A76","pred":"tao:has_database_id","subj":"76","obj":"MESH:D008107"},{"id":"A77","pred":"tao:has_database_id","subj":"77","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"To navigate through the stormy unchartered ocean of SARS‐coV‐2 infections and coronavirus disease 2019 (COVID‐19), all practicing hepatologists and other clinicians caring for patients with liver disease need guidance based on the best documented and rapidly evolving knowledge regarding SARS‐CoV‐2 infection and COVID‐19. Prevention of SARS‐CoV‐2 transmission requires the redesign of patient workflow and other measures ensuring delivery of elective and emergency hepatology services without compromising the safety of patients and medical personnel. 1 , 2 Moreover, prevention of severe COVID‐19 and related mortality requires updating management of persons with chronic liver disease (CLD) to diagnose COVID‐19 and being vigilant for drug‐drug interactions and other potential complications of COVID‐19 in persons with CLD. 3 To respond to an urgent need for such information, the Asian Pacific Association for the Study of the Liver (APASL) recently published recommendations of an expert committee to guide infection control and clinical management of patients with CLD during the COVID‐19 pandemic. 4 Previously, two other regional liver associations, American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL), convened expert panels with the same objectives. 5 , 6 This review summarizes the recommendations of the three liver associations for clinical practices to prevent SARS‐CoV‐2 transmission and protect persons with CLD from health risks posed by the emerging COVID‐19 pandemic (Table 1)."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T9","span":{"begin":190,"end":195},"obj":"Body_part"},{"id":"T10","span":{"begin":676,"end":681},"obj":"Body_part"},{"id":"T11","span":{"begin":935,"end":940},"obj":"Body_part"},{"id":"T12","span":{"begin":1143,"end":1148},"obj":"Body_part"},{"id":"T13","span":{"begin":1201,"end":1206},"obj":"Body_part"},{"id":"T14","span":{"begin":1270,"end":1275},"obj":"Body_part"},{"id":"T15","span":{"begin":1397,"end":1402},"obj":"Body_part"}],"attributes":[{"id":"A9","pred":"uberon_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"A10","pred":"uberon_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"A11","pred":"uberon_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"A12","pred":"uberon_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"A13","pred":"uberon_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"A14","pred":"uberon_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"A15","pred":"uberon_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"}],"text":"To navigate through the stormy unchartered ocean of SARS‐coV‐2 infections and coronavirus disease 2019 (COVID‐19), all practicing hepatologists and other clinicians caring for patients with liver disease need guidance based on the best documented and rapidly evolving knowledge regarding SARS‐CoV‐2 infection and COVID‐19. Prevention of SARS‐CoV‐2 transmission requires the redesign of patient workflow and other measures ensuring delivery of elective and emergency hepatology services without compromising the safety of patients and medical personnel. 1 , 2 Moreover, prevention of severe COVID‐19 and related mortality requires updating management of persons with chronic liver disease (CLD) to diagnose COVID‐19 and being vigilant for drug‐drug interactions and other potential complications of COVID‐19 in persons with CLD. 3 To respond to an urgent need for such information, the Asian Pacific Association for the Study of the Liver (APASL) recently published recommendations of an expert committee to guide infection control and clinical management of patients with CLD during the COVID‐19 pandemic. 4 Previously, two other regional liver associations, American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL), convened expert panels with the same objectives. 5 , 6 This review summarizes the recommendations of the three liver associations for clinical practices to prevent SARS‐CoV‐2 transmission and protect persons with CLD from health risks posed by the emerging COVID‐19 pandemic (Table 1)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T25","span":{"begin":52,"end":56},"obj":"Disease"},{"id":"T26","span":{"begin":63,"end":73},"obj":"Disease"},{"id":"T27","span":{"begin":78,"end":102},"obj":"Disease"},{"id":"T28","span":{"begin":104,"end":112},"obj":"Disease"},{"id":"T29","span":{"begin":190,"end":203},"obj":"Disease"},{"id":"T30","span":{"begin":288,"end":292},"obj":"Disease"},{"id":"T31","span":{"begin":299,"end":308},"obj":"Disease"},{"id":"T32","span":{"begin":313,"end":321},"obj":"Disease"},{"id":"T33","span":{"begin":337,"end":341},"obj":"Disease"},{"id":"T34","span":{"begin":592,"end":600},"obj":"Disease"},{"id":"T35","span":{"begin":676,"end":689},"obj":"Disease"},{"id":"T36","span":{"begin":691,"end":694},"obj":"Disease"},{"id":"T37","span":{"begin":708,"end":716},"obj":"Disease"},{"id":"T38","span":{"begin":800,"end":808},"obj":"Disease"},{"id":"T39","span":{"begin":825,"end":828},"obj":"Disease"},{"id":"T40","span":{"begin":1016,"end":1025},"obj":"Disease"},{"id":"T41","span":{"begin":1075,"end":1078},"obj":"Disease"},{"id":"T42","span":{"begin":1090,"end":1098},"obj":"Disease"},{"id":"T43","span":{"begin":1450,"end":1454},"obj":"Disease"},{"id":"T44","span":{"begin":1499,"end":1502},"obj":"Disease"},{"id":"T45","span":{"begin":1543,"end":1551},"obj":"Disease"}],"attributes":[{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A26","pred":"mondo_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A29","pred":"mondo_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/MONDO_0005154"},{"id":"A30","pred":"mondo_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A31","pred":"mondo_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A32","pred":"mondo_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A33","pred":"mondo_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A34","pred":"mondo_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A35","pred":"mondo_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/MONDO_0005154"},{"id":"A36","pred":"mondo_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/MONDO_0008964"},{"id":"A37","pred":"mondo_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A38","pred":"mondo_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A39","pred":"mondo_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/MONDO_0008964"},{"id":"A40","pred":"mondo_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A41","pred":"mondo_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/MONDO_0008964"},{"id":"A42","pred":"mondo_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A43","pred":"mondo_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A44","pred":"mondo_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/MONDO_0008964"},{"id":"A45","pred":"mondo_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"To navigate through the stormy unchartered ocean of SARS‐coV‐2 infections and coronavirus disease 2019 (COVID‐19), all practicing hepatologists and other clinicians caring for patients with liver disease need guidance based on the best documented and rapidly evolving knowledge regarding SARS‐CoV‐2 infection and COVID‐19. Prevention of SARS‐CoV‐2 transmission requires the redesign of patient workflow and other measures ensuring delivery of elective and emergency hepatology services without compromising the safety of patients and medical personnel. 1 , 2 Moreover, prevention of severe COVID‐19 and related mortality requires updating management of persons with chronic liver disease (CLD) to diagnose COVID‐19 and being vigilant for drug‐drug interactions and other potential complications of COVID‐19 in persons with CLD. 3 To respond to an urgent need for such information, the Asian Pacific Association for the Study of the Liver (APASL) recently published recommendations of an expert committee to guide infection control and clinical management of patients with CLD during the COVID‐19 pandemic. 4 Previously, two other regional liver associations, American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL), convened expert panels with the same objectives. 5 , 6 This review summarizes the recommendations of the three liver associations for clinical practices to prevent SARS‐CoV‐2 transmission and protect persons with CLD from health risks posed by the emerging COVID‐19 pandemic (Table 1)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T22","span":{"begin":190,"end":195},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T23","span":{"begin":190,"end":195},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T24","span":{"begin":676,"end":681},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T25","span":{"begin":676,"end":681},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T26","span":{"begin":935,"end":940},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T27","span":{"begin":935,"end":940},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T28","span":{"begin":1143,"end":1148},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T29","span":{"begin":1143,"end":1148},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T30","span":{"begin":1201,"end":1206},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T31","span":{"begin":1201,"end":1206},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T32","span":{"begin":1270,"end":1275},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T33","span":{"begin":1270,"end":1275},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T34","span":{"begin":1321,"end":1331},"obj":"http://purl.obolibrary.org/obo/BFO_0000030"},{"id":"T35","span":{"begin":1397,"end":1402},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T36","span":{"begin":1397,"end":1402},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"}],"text":"To navigate through the stormy unchartered ocean of SARS‐coV‐2 infections and coronavirus disease 2019 (COVID‐19), all practicing hepatologists and other clinicians caring for patients with liver disease need guidance based on the best documented and rapidly evolving knowledge regarding SARS‐CoV‐2 infection and COVID‐19. Prevention of SARS‐CoV‐2 transmission requires the redesign of patient workflow and other measures ensuring delivery of elective and emergency hepatology services without compromising the safety of patients and medical personnel. 1 , 2 Moreover, prevention of severe COVID‐19 and related mortality requires updating management of persons with chronic liver disease (CLD) to diagnose COVID‐19 and being vigilant for drug‐drug interactions and other potential complications of COVID‐19 in persons with CLD. 3 To respond to an urgent need for such information, the Asian Pacific Association for the Study of the Liver (APASL) recently published recommendations of an expert committee to guide infection control and clinical management of patients with CLD during the COVID‐19 pandemic. 4 Previously, two other regional liver associations, American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL), convened expert panels with the same objectives. 5 , 6 This review summarizes the recommendations of the three liver associations for clinical practices to prevent SARS‐CoV‐2 transmission and protect persons with CLD from health risks posed by the emerging COVID‐19 pandemic (Table 1)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T11","span":{"begin":740,"end":744},"obj":"Chemical"},{"id":"T12","span":{"begin":745,"end":749},"obj":"Chemical"}],"attributes":[{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"To navigate through the stormy unchartered ocean of SARS‐coV‐2 infections and coronavirus disease 2019 (COVID‐19), all practicing hepatologists and other clinicians caring for patients with liver disease need guidance based on the best documented and rapidly evolving knowledge regarding SARS‐CoV‐2 infection and COVID‐19. Prevention of SARS‐CoV‐2 transmission requires the redesign of patient workflow and other measures ensuring delivery of elective and emergency hepatology services without compromising the safety of patients and medical personnel. 1 , 2 Moreover, prevention of severe COVID‐19 and related mortality requires updating management of persons with chronic liver disease (CLD) to diagnose COVID‐19 and being vigilant for drug‐drug interactions and other potential complications of COVID‐19 in persons with CLD. 3 To respond to an urgent need for such information, the Asian Pacific Association for the Study of the Liver (APASL) recently published recommendations of an expert committee to guide infection control and clinical management of patients with CLD during the COVID‐19 pandemic. 4 Previously, two other regional liver associations, American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL), convened expert panels with the same objectives. 5 , 6 This review summarizes the recommendations of the three liver associations for clinical practices to prevent SARS‐CoV‐2 transmission and protect persons with CLD from health risks posed by the emerging COVID‐19 pandemic (Table 1)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T26","span":{"begin":0,"end":322},"obj":"Sentence"},{"id":"T27","span":{"begin":323,"end":552},"obj":"Sentence"},{"id":"T28","span":{"begin":553,"end":829},"obj":"Sentence"},{"id":"T29","span":{"begin":830,"end":1108},"obj":"Sentence"},{"id":"T30","span":{"begin":1109,"end":1332},"obj":"Sentence"},{"id":"T31","span":{"begin":1333,"end":1571},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"To navigate through the stormy unchartered ocean of SARS‐coV‐2 infections and coronavirus disease 2019 (COVID‐19), all practicing hepatologists and other clinicians caring for patients with liver disease need guidance based on the best documented and rapidly evolving knowledge regarding SARS‐CoV‐2 infection and COVID‐19. Prevention of SARS‐CoV‐2 transmission requires the redesign of patient workflow and other measures ensuring delivery of elective and emergency hepatology services without compromising the safety of patients and medical personnel. 1 , 2 Moreover, prevention of severe COVID‐19 and related mortality requires updating management of persons with chronic liver disease (CLD) to diagnose COVID‐19 and being vigilant for drug‐drug interactions and other potential complications of COVID‐19 in persons with CLD. 3 To respond to an urgent need for such information, the Asian Pacific Association for the Study of the Liver (APASL) recently published recommendations of an expert committee to guide infection control and clinical management of patients with CLD during the COVID‐19 pandemic. 4 Previously, two other regional liver associations, American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL), convened expert panels with the same objectives. 5 , 6 This review summarizes the recommendations of the three liver associations for clinical practices to prevent SARS‐CoV‐2 transmission and protect persons with CLD from health risks posed by the emerging COVID‐19 pandemic (Table 1)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T9","span":{"begin":190,"end":203},"obj":"Phenotype"},{"id":"T10","span":{"begin":676,"end":689},"obj":"Phenotype"},{"id":"T11","span":{"begin":1201,"end":1215},"obj":"Phenotype"}],"attributes":[{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0001392"},{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0001392"},{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0001392"}],"text":"To navigate through the stormy unchartered ocean of SARS‐coV‐2 infections and coronavirus disease 2019 (COVID‐19), all practicing hepatologists and other clinicians caring for patients with liver disease need guidance based on the best documented and rapidly evolving knowledge regarding SARS‐CoV‐2 infection and COVID‐19. Prevention of SARS‐CoV‐2 transmission requires the redesign of patient workflow and other measures ensuring delivery of elective and emergency hepatology services without compromising the safety of patients and medical personnel. 1 , 2 Moreover, prevention of severe COVID‐19 and related mortality requires updating management of persons with chronic liver disease (CLD) to diagnose COVID‐19 and being vigilant for drug‐drug interactions and other potential complications of COVID‐19 in persons with CLD. 3 To respond to an urgent need for such information, the Asian Pacific Association for the Study of the Liver (APASL) recently published recommendations of an expert committee to guide infection control and clinical management of patients with CLD during the COVID‐19 pandemic. 4 Previously, two other regional liver associations, American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL), convened expert panels with the same objectives. 5 , 6 This review summarizes the recommendations of the three liver associations for clinical practices to prevent SARS‐CoV‐2 transmission and protect persons with CLD from health risks posed by the emerging COVID‐19 pandemic (Table 1)."}